Diabetic cardiomyopathy and oxidative stress: Role of antioxidants

Cardiovascular and Hematological Agents in Medicinal Chemistry

Volumn 9, Issue 4, 2011, Pages 225-230

  Thandavarayan, Rajarajan A ^a   Giridharan, Vijayasree V ^a   Watanabe, Kenichi ^a   Konishi, Tetsuya ^a  

^a NIIGATA UNIVERSITY OF PHARMACY AND APPLIED LIFE SCIENCES   (Japan)

Author keywords

Antioxidants; Apoptosis; Curcumin; Diabetic cardiomyopathy; Edaravone; Fibrosis; Hypertrophy; Oxidative stress; Resveratrol; Tempol

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; CURCUMIN; GLUCOSE; NITROUS OXIDE REDUCTASE; NORPHENAZONE; RESVERATROL; TEMPOL; THIOREDOXIN 1;

APOPTOSIS; CARDIOVASCULAR EFFECT; DIABETIC CARDIOMYOPATHY; DIABETIC PATIENT; ENZYME ACTIVITY; ENZYME INDUCTION; FIBROSIS; GENE EXPRESSION; GENE THERAPY; GLUCOSE BLOOD LEVEL; GROWTH REGULATION; HEART VENTRICLE HYPERTROPHY; HUMAN; HYDROXYLATION; NONHUMAN; OXIDATIVE STRESS; REVIEW; TRANSCRIPTION REGULATION;

ANIMALS; ANTIOXIDANTS; CARDIOTONIC AGENTS; DIABETIC CARDIOMYOPATHIES; HEART; HUMANS; MYOCARDIUM; OXIDATIVE STRESS;

EID: 82255164094     PISSN: 18715257     EISSN: 18756182     Source Type: Journal    
DOI: 10.2174/187152511798120877     Document Type: Review

References (72)

1. King, H.; Aubert, R.E.; Herman, W.H. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care, 1998, 21(9), 1414-1431.
2. Lloyd-Jones, D.; Adams, R.J.; Brown, T.M.; Carnethon, M.; Dai, S.; De Simone, G.; Ferguson, T.B.; Ford, E.; Furie, K.; Gillespie, C.; Go, A.; Greenlund, K.; Haase, N.; Hailpern, S.; Ho, P.M.; Howard, V.; Kissela, B.; Kittner, S.; Lackland, D.; Lisabeth, L.; Marelli, A.; McDermott, M.M.; Meigs, J.; Mozaffarian, D.; Musso-lino, M.; Nichol, G.; Roger, V.L.; Rosamond, W.; Sacco, R.; Sor-lie, P.; Stafford, R.; Thom, T.; Wasserthiel-Smoller, S.; Wong, N.D.; Wylie-Rosett, J. Executive summary: heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation, 2010, 121(7), 948-954.
3. Rubler, S.; Dlugash, J.; Yuceoglu, Y.Z.; Kumral, T.; Branwood, A.W.; Grishman, A. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am. J. of Cardiol., 1972, 30(6), 595-602.
4. Fang, Z.Y.; Prins, J.B.; Marwick, T.H. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr. Rev., 2004, 25(4), 543-567.
5. Cai, L.; Kang, Y.J. Cell death and diabetic cardiomyopathy. Cardiovasc. Toxicol., 2003, 3(3), 219-228.
6. Li, X.; Xu, Z.; Li, S.; Rozanski, G.J. Redox regulation of Ito remodeling in diabetic rat heart. Am. J. Physiol. Heart Circ. Physiol., 2005, 288(3), H1417-1424.
7. Cai, L.; Kang, Y.J. Oxidative stress and diabetic cardiomyopathy: a brief review. Cardiovasc. Toxicol., 2001, 1(3), 181-193.
8. Pang, Y.; Hunton, D.L.; Bounelis, P.; Marchase, R.B. Hyperglyce-mia inhibits capacitative calcium entry and hypertrophy in neonatal cardiomyocytes. Diabetes, 2002, 51(12), 3461-3467.
9. Ligeti, L.; Szenczi, O.; Prestia, C.M.; Szabo, C.; Horvath, K.; Marcsek, Z.L.; van Stiphout, R.G.; van Riel, N.A.; Op den Buijs, J.; Van der Vusse, G.J.; Ivanics, T. Altered calcium handling is an early sign of streptozotocin-induced diabetic cardiomyopathy. Int. J. Mol. Med., 2006, 17(6), 1035-1043.
10. Finck, B.N.; Han, X.; Courtois, M.; Aimond, F.; Nerbonne, J.M.; Kovacs, A.; Gross, R.W.; Kelly, D.P. A critical role for PPARalphamediated lipotoxicity in the pathogenesis of diabetic cardio-myopathy: modulation by dietary fat content. Proc. Natl. Acad. Sci. USA, 2003, 100(3), 1226-1231.
11. Diwan, A.; Tran, T.; Misra, A.; Mann, D.L. Inflammatory media-tors and the failing heart: a translational approach. Curr. Mol. Med., 2003, 3(2), 161-182.
12. Brownlee, M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes, 2005, 54(6), 1615-1625.
13. Bell, D.S. Diabetic cardiomyopathy. A unique entity or a complication of coronary artery disease? Diabetes Care, 1995, 18(5), 708-714.
14. Rodrigues, B.; McNeill, J.H. The diabetic heart: metabolic causes for the development of a cardiomyopathy. Cardiovasc. Res., 1992, 26(10), 913-922.
15. Spector, K.S. Diabetic cardiomyopathy. Clin. Cardiol., 1998, 21(12), 885-887.
16. Fein, F.S.; Sonnenblick, E.H. Diabetic cardiomyopathy. Prog. Cardiovas.c Dis., 1985, 27(4), 255-270.
17. Solang, L.; Malmberg, K.; Ryden, L. Diabetes mellitus and congestive heart failure. Further knowledge needed. Eur. Heart J., 1999, 20(11), 789-795.
18. Bauters, C.; Lamblin, N.; Mc Fadden, E.P.; Van Belle, E.; Millaire, A.; de Groote, P. Influence of diabetes mellitus on heart failure risk and outcome. Cardiovasc. Diabetol., 2003, 2, 1-16.
19. Frustaci, A.; Kajstura, J.; Chimenti, C.; Jakoniuk, I.; Leri, A.; Maseri, A.; Nadal-Ginard, B.; Anversa, P. Myocardial cell death in human diabetes. Circ. Res., 2000, 87(12), 1123-1132.
20. Freude, B.; Masters, T.N.; Robicsek, F.; Fokin, A.; Kostin, S.; Zimmermann, R.; Ullmann, C.; Lorenz-Meyer, S.; Schaper, J. Apoptosis is initiated by myocardial ischemia and executed during reperfusion. J. Mol. Cell. Cardiol., 2000, 32(2), 197-208.
21. Guerra, S.; Leri, A.; Wang, X.; Finato, N.; Di Loreto, C.; Beltrami, C.A.; Kajstura, J.; Anversa, P. Myocyte death in the failing human heart is gender dependent. Circ. Res., 1999, 85(9), 856-866.
22. Sam, F.; Sawyer, D.B.; Chang, D.L.; Eberli, F.R.; Ngoy, S.; Jain, M.; Amin, J.; Apstein, C.S.; Colucci, W.S. Progressive left ventricular remodeling and apoptosis late after myocardial infarction in mouse heart. Am. J. Physiol. Heart. Circ. Physio.l, 2000, 279(1), H422-428.
23. Zhou, Y.T.; Grayburn, P.; Karim, A.; Shimabukuro, M.; Higa, M.; Baetens, D.; Orci, L.; Unger, R.H. Lipotoxic heart disease in obese rats: implications for human obesity. Proc. Natl. Acad. Sci. USA, 2000, 97(4), 1784-1789.
24. Tea, B.S.; Dam, T.V.; Moreau, P.; Hamet, P.; deBlois, D. Apoptosis during regression of cardiac hypertrophy in spontaneously hypertensive rats. Temporal regulation and spatial heterogeneity. Hypertension, 1999, 34(2), 229-235.
25. Fiordaliso, F.; Li, B.; Latini, R.; Sonnenblick, E.H.; Anversa, P.; Leri, A.; Kajstura, J. Myocyte death in streptozotocin-induced diabetes in rats in angiotensin II-dependent. Lab. Invest., 2000, 80(4), 513-527.
26. Kajstura, J.; Fiordaliso, F.; Andreoli, A.M.; Li, B.; Chimenti, S.; Medow, M.S.; Limana, F.; Nadal-Ginard, B.; Leri, A.; Anversa, P. IGF-1 overexpression inhibits the development of diabetic cardiomyopathy and angiotensin II-mediated oxidative stress. Diabetes, 2001, 50(6), 1414-1424.
27. Cai, L.; Li, W.; Wang, G.; Guo, L.; Jiang, Y.; Kang, Y.J. Hyper-glycemia-induced apoptosis in mouse myocardium: mitochondrial cytochrome C-mediated caspase-3 activation pathway. Diabetes, 2002, 51(6), 1938-1948.
28. Thandavarayan, R.A.; Watanabe, K.; Ma, M.; Gurusamy, N.; Veeraveedu, P.T.; Konishi, T.; Zhang, S.; Muslin, A.J.; Kodama, M.; Aizawa, Y. Dominant-negative p38alpha mitogen-activated protein kinase prevents cardiac apoptosis and remodeling after streptozotocin-induced diabetes mellitus. Am. J. Physiol. Heart Circ. Physiol., 2009, 297(3), H911-919.
29. Barouch, L.A.; Berkowitz, D.E.; Harrison, R.W.; O'Donnell, C.P.; Hare, J.M. Disruption of leptin signaling contributes to cardiac hypertrophy independently of body weight in mice. Circulation, 2003, 108(6), 754-759.
30. Nunoda, S.; Genda, A.; Sugihara, N.; Nakayama, A.; Mizuno, S.; Takeda, R. Quantitative approach to the histopathology of the biopsied right ventricular myocardium in patients with diabetes mellitus. Heart Vessels, 1985, 1(1), 43-47.
31. Lorell, B.H.; Carabello, B.A. Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation, 2000, 102(4), 470-479.
32. Wilson, J.M.; Villareal, R.P.; Hariharan, R.; Massumi, A.; Muth-upillai, R.; Flamm, S.D. Magnetic resonance imaging of myocar-dial fibrosis in hypertrophic cardiomyopathy. Tex. Heart Inst. J., 2002, 29(3), 176-180.
33. Shimizu, M.; Umeda, K.; Sugihara, N.; Yoshio, H.; Ino, H.; Takeda, R.; Okada, Y.; Nakanishi, I. Collagen remodelling in myocardia of patients with diabetes. J. Clin. Pathol., 1993, 46(1), 32-36.
34. Eghbali, M. Cellular origin and distribution of transforming growth factor-beta in the normal rat myocardium. Cell Tissue Res., 1989, 256(3), 553-558.
35. Matata, B.M.; Galinanes, M. Cardiopulmonary bypass exacerbates oxidative stress but does not increase proinflammatory cytokine release in patients with diabetes compared with patients without diabetes: regulatory effects of exogenous nitric oxide. J. Thorac. Cardiovasc. Surg., 2000, 120(1), 1-11.
36. Levy, A.P.; Gerstein, H.C.; Miller-Lotan, R.; Ratner, R.; McQueen, M.; Lonn, E.; Pogue, J. The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglo-bin phenotypes. Diabetes Care, 2004, 27(11), 2767.
37. Milman, U.; Blum, S.; Shapira, C.; Aronson, D.; Miller-Lotan, R.; Anbinder, Y.; Alshiek, J.; Bennett, L.; Kostenko, M.; Landau, M.; Keidar, S.; Levy, Y.; Khemlin, A.; Radan, A.; Levy, A.P. Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both type 2 diabetes mellitus and the haptoglobin 2-2 genotype: a prospective doubleblinded clinical trial. Arterioscler. Thromb. Vasc. Biol., 2008, 28(2), 341-347.
38. Boaz, M.; Smetana, S.; Weinstein, T.; Matas, Z.; Gafter, U.; Iaina, A.; Knecht, A.; Weissgarten, Y.; Brunner, D.; Fainaru, M.; Green, M.S. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet, 2000, 356(9237), 1213-1218.
39. Stephens, N.G.; Parsons, A.; Schofield, P.M.; Kelly, F.; Cheese-man, K.; Mitchinson, M.J. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet, 1996, 347(9004), 781-786.
40. Singh, R.B.; Niaz, M.A.; Rastogi, S.S.; Rastogi, S. Usefulness of antioxidant vitamins in suspected acute myocardial infarction (the Indian experiment of infarct survival-3). Am. J. Cardiol., 1996, 77(4), 232-236.
41. Yusuf, S.; Dagenais, G.; Pogue, J.; Bosch, J.; Sleight, P. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med., 2000, 342(3), 154-160.
42. Lee, I.M.; Cook, N.R.; Gaziano, J.M.; Gordon, D.; Ridker, P.M.; Manson, J.E.; Hennekens, C.H.; Buring, J.E. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA, 2005, 294(1), 56-65.
43. Salonen, J.T.; Nyyssonen, K.; Salonen, R.; Lakka, H.M.; Kaikkonen, J.; Porkkala-Sarataho, E.; Voutilainen, S.; Lakka, T.A.; Rissanen, T.; Leskinen, L.; Tuomainen, T.P.; Valkonen, V.P.; Ristonmaa, U.; Poulsen, H.E. Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) study: a randomized trial of the effect of vitamins E and C on 3-year progression of carotid atherosclerosis. J. Intern. Med., 2000, 248(5), 377-386.
44. Hodis, H.N.; Mack, W.J.; LaBree, L.; Mahrer, P.R.; Sevanian, A.; Liu, C.R.; Liu, C.H.; Hwang, J.; Selzer, R.H.; Azen, S.P. Alpha-tocopherol supplementation in healthy individuals reduces low-density lipoprotein oxidation but not atherosclerosis: the Vitamin E Atherosclerosis Prevention Study (VEAPS). Circulation, 2002, 106(12), 1453-1459.
45. Nassar, T.; Kadery, B.; Lotan, C.; Da'as, N.; Kleinman, Y.; Haj-Yehia, A. Effects of the superoxide dismutase-mimetic compound tempol on endothelial dysfunction in streptozotocin-induced diabetic rats. Eur. J. Pharmacol., 2002, 436(1-2), 111-118.
46. Jagadeesha, D.K.; Lindley, T.E.; Deleon, J.; Sharma, R.V.; Miller, F.; Bhalla, R.C. Tempol therapy attenuates medial smooth muscle cell apoptosis and neointima formation after balloon catheter injury in carotid artery of diabetic rats. Am. J. Physiol. Heart Circ. Physiol., 2005, 289(3), H1047-1053.
47. Gurusamy, N.; Watanabe, K.; Ma, M.; Prakash, P.; Hirabayashi, K.; Zhang, S.; Muslin, A.J.; Kodama, M.; Aizawa, Y. Glycogen synthase kinase 3beta together with 14-3-3 protein regulates diabetic cardiomyopathy: effect of losartan and tempol. FEBS Letters, 2006, 580(8), 1932-1940.
48. Soleas, G.J.; Diamandis, E.P.; Goldberg, D.M. Resveratrol: a molecule whose time has come? And gone? Clin. Biochem., 1997, 30(2), 91-113.
49. Fremont, L. Biological effects of resveratrol. Life Sci., 2000, 66(8), 663-673.
50. Ray, P.S.; Maulik, G.; Cordis, G.A.; Bertelli, A.A.; Bertelli, A.; Das, D.K. The red wine antioxidant resveratrol protects isolated rat hearts from ischemia reperfusion injury. Free Radic. Biol. Med., 1999, 27(1-2), 160-169.
51. Hattori, R.; Otani, H.; Maulik, N.; Das, D.K. Pharmacological preconditioning with resveratrol: role of nitric oxide. Am. J. Physiol. Heart Circ. Physiol., 2002, 282(6), H1988-1995.
52. Su, H.C.; Hung, L.M.; Chen, J.K. Resveratrol, a red wine antioxidant, possesses an insulin-like effect in streptozotocin-induced diabetic rats. Am. J. Physiol. Endocrinol. Metab., 2006, 290(6), E1339-1346.
53. Miatello, R.; Vazquez, M.; Renna, N.; Cruzado, M.; Zumino, A.P.; Risler, N. Chronic administration of resveratrol prevents biochemical cardiovascular changes in fructose-fed rats. Am. J. Hypertens., 2005, 18(6), 864-870.
54. Lekli, I.; Szabo, G.; Juhasz, B.; Das, S.; Das, M.; Varga, E.; Szendrei, L.; Gesztelyi, R.; Varadi, J.; Bak, I.; Das, D.K.; Tosaki, A. Protective mechanisms of resveratrol against ischemiareperfusioninduced damage in hearts obtained from Zucker obese rats: the role of GLUT-4 and endothelin. Am. J. Physiol. Heart Circ. Physiol., 2008, 294(2), H859-866.
55. Baur, J.A.; Pearson, K.J.; Price, N.L.; Jamieson, H.A.; Lerin, C.; Kalra, A.; Prabhu, V.V.; Allard, J.S.; Lopez-Lluch, G.; Lewis, K.; Pistell, P.J.; Poosala, S.; Becker, K.G.; Boss, O.; Gwinn, D.; Wang, M.; Ramaswamy, S.; Fishbein, K.W.; Spencer, R.G.; Lakatta, E.G.; Le Couteur, D.; Shaw, R.J.; Navas, P.; Puigserver, P.; Ingram, D.K.; de Cabo, R.; Sinclair, D.A. Resveratrol improves health and survival of mice on a high-calorie diet. Nature, 2006, 444(7117), 337-342.
56. Thirunavukkarasu, M.; Penumathsa, S.V.; Koneru, S.; Juhasz, B.; Zhan, L.; Otani, H.; Bagchi, D.; Das, D.K.; Maulik, N. Resveratrol alleviates cardiac dysfunction in streptozotocin-induced diabetes: Role of nitric oxide, thioredoxin, and heme oxygenase. Free Radic. Biol. Med., 2007, 43(5), 720-729.
57. Ammon, H.P.; Wahl, M.A. Pharmacology of Curcuma longa. Planta Med, 1991, 57(1), 1-7.
58. Bengmark, S. Curcumin, an atoxic antioxidant and natural NFkap-paB, cyclooxygenase-2, lipooxygenase, and inducible nitric oxide synthase inhibitor: a shield against acute and chronic diseases. JPEN J. Parenter. Enteral. Nutr., 2006, 30(1), 45-51.
59. Arun, N.; Nalini, N. Efficacy of turmeric on blood sugar and polyol pathway in diabetic albino rats. Plant Foods Hum. Nutr., 2002, 57(1), 41-52.
60. Balasubramanyam, M.; Koteswari, A.A.; Kumar, R.S.; Monickaraj, S.F.; Maheswari, J.U.; Mohan, V. Curcumin-induced inhibition of cellular reactive oxygen species generation: novel therapeutic implications. J. Biosci., 2003, 28(6), 715-721.
61. Nishiyama, T.; Mae, T.; Kishida, H.; Tsukagawa, M.; Mimaki, Y.; Kuroda, M.; Sashida, Y.; Takahashi, K.; Kawada, T.; Nakagawa, K.; Kitahara, M. Curcuminoids and sesquiterpenoids in turmeric (Curcuma longa L.) suppress an increase in blood glucose level in type 2 diabetic KK-Ay mice. J. Agric. Food Chem., 2005, 53(4), 959-963.
62. Srinivasan, M. Effect of curcumin on blood sugar as seen in a diabetic subject. Indian J. Med. Sci., 1972, 26(4), 269-270.
63. Babu, P.S.; Srinivasan, K. Influence of dietary curcumin and cholesterol on the progression of experimentally induced diabetes in albino rat. Mol. Cell. Biochem., 1995, 152(1), 13-21.
64. Mahesh, T.; Sri Balasubashini, M.M.; Menon, V.P. Photo-irradiated curcumin supplementation in streptozotocin-induced diabetic rats: effect on lipid peroxidation. Therapie, 2004, 59(6), 639-644.
65. Farhangkhoee, H.; Khan, Z.A.; Chen, S.; Chakrabarti, S. Differential effects of curcumin on vasoactive factors in the diabetic rat heart. Nutr. Metab. (Lond), 2006, 3, 27.
66. Feng, B.; Chen, S.; Chiu, J.; George, B.; Chakrabarti, S. Regulation of cardiomyocyte hypertrophy in diabetes at the transcriptional level. Am. J. Physiol. Endocrinol. Metab., 2008, 294(6), E1119-1126.
67. Shimazaki, H.; Watanabe, K.; Veeraveedu, P.T.; Harima, M.; Thandavarayan, R.A.; Arozal, W.; Tachikawa, H.; Kodama, M.; Aizawa, Y. The antioxidant edaravone attenuates ER-stress-mediated cardiac apoptosis and dysfunction in rats with auto-immune myocarditis. Free Radic. Res., 2010, 44(9), 1082-1090.
68. Hayashi, T.; Mori, T.; Sohmiya, K.; Okada, Y.; Inamoto, S.; Okuda, N.; Mori, H.; Kitaura, Y. Efficacy of edaravone, a free radical scavenger, on left ventricular function and structure in diabetes mellitus. J. Cardiovasc. Pharmacol., 2003, 41(6), 923-929.
69. Samuel, S.M.; Thirunavukkarasu, M.; Penumathsa, S.V.; Koneru, S.; Zhan, L.; Maulik, G.; Sudhakaran, P.R.; Maulik, N. Thioredoxin-1 gene therapy enhances angiogenic signaling and reduces ventricular remodeling in infarcted myocardium of diabetic rats. Circulation, 2010, 121(10), 1244-1255.
70. Nordberg, J.; Arner, E.S. Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. Free Radic. Biol. Med., 2001, 31(11), 1287-1312.
71. Taniguchi, Y.; Taniguchi-Ueda, Y.; Mori, K.; Yodoi, J. A novel promoter sequence is involved in the oxidative stress-induced expression of the adult T-cell leukemia-derived factor (ADF)/human thioredoxin (Trx) gene. Nucleic Acids Res., 1996, 24(14), 2746-2752.
72. Hoshino, Y.; Shioji, K.; Nakamura, H.; Masutani, H.; Yodoi, J. From oxygen sensing to heart failure: role of thioredoxin. Antioxid. Redox Signal., 2007, 9(6), 689-699.